^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zanzalintinib (XL092)

    i
    Other names: XL092, XL-092, XL 092
    Associations

    News

    Trials
    Company:
    Exelixis
    Drug class:
    Tyrosine kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    18d
    NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Northwell Health
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Zynyz (retifanlimab-dlwr) • zanzalintinib (XL092)
    18d
    NAPOLEON: Zanzalintinib in Men With Aggressive Variant Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Deepak Kilari | Trial completion date: Dec 2027 --> Jul 2029 | Trial primary completion date: Dec 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CHGA (Chromogranin A)
    |
    zanzalintinib (XL092)
    19d
    Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Trial completion date: Jul 2031 --> Jan 2034 | Trial primary completion date: Aug 2026 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • zanzalintinib (XL092)
    26d
    A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=303, Recruiting, Exelixis | N=75 --> 303
    Enrollment change
    |
    zanzalintinib (XL092)
    1m
    XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=73, Recruiting, Northwestern University | N=29 --> 73 | Trial completion date: Jul 2029 --> Jul 2033
    Enrollment change • Trial completion date
    |
    zanzalintinib (XL092)
    2ms
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Trial primary completion date: Nov 2028 --> May 2031 | Trial completion date: Oct 2033 --> Apr 2036
    Trial completion date • Trial primary completion date
    |
    eribulin mesylate • zanzalintinib (XL092)
    2ms
    ZENITH: Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stuthi Perimbeti
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • zanzalintinib (XL092)
    2ms
    Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (clinicaltrials.gov)
    P3, N=5000, Not yet recruiting, Exelixis
    New P3 trial
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • enzalutamide • Cabometyx (cabozantinib tablet) • abiraterone acetate • prednisone • zanzalintinib (XL092)
    2ms
    A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (clinicaltrials.gov)
    P2, N=100, Recruiting, Exelixis | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zanzalintinib (XL092)
    2ms
    Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Guru Sonpavde | Trial completion date: Mar 2029 --> Jun 2029 | Initiation date: Feb 2026 --> Jun 2026
    Trial completion date • Trial initiation date
    |
    CD4 (CD4 Molecule)
    |
    zanzalintinib (XL092)
    2ms
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    2ms
    Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Cdactin-O (CBM588) • zanzalintinib (XL092)